ERCC5 promoter polymorphisms at –763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer
نویسندگان
چکیده
منابع مشابه
Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy
The promoter is the center for regulation of gene transcription due to containing numerous transcription factor binding sites. The aim of the study was to determine whether genetic variations at excision repair cross complementation group 5 (ERCC5) promoter could affect transcription factor binding and whether such single nucleotide polymorphism (SNP)-dependent binding could affect gene express...
متن کاملTWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
The epithelial-mesenchymal transition (EMT) is an important mechanism of resistance to angiogenesis inhibition. The ability of EMT pathway genetic variants to predict the efficacy of antiangiogenic therapy is unknown. We analyzed associations between functional SNPs in EMT-related genes and outcomes in metastatic colorectal cancer (mCRC) patients undergoing first-line bevacizumab-based chemothe...
متن کاملStudy of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
This study was designed to evaluate the effect of excision repair crosscomplementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms ontreatment outcomes in Iranian patients receiving oxaliplatin-based regimens forcolorectal (CRC) and gastric cancers (GC). Patients, who were candidates to receiveoxaliplatin-based chemotherapy, entered into the study. In 2-week in...
متن کاملStudy of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
This study was designed to evaluate the effect of excision repair crosscomplementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms ontreatment outcomes in Iranian patients receiving oxaliplatin-based regimens forcolorectal (CRC) and gastric cancers (GC). Patients, who were candidates to receiveoxaliplatin-based chemotherapy, entered into the study. In 2-week in...
متن کاملInterstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
OBJECTIVE Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare. METHODS We reviewed 104 colorectal cancer patients treated with standard chemotherapy with bevacizumab and examined the incidence of interstitial lung disease and its clinical features. RESULTS We identified interstitial lung disease in four patients (3.85%). All pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2009
ISSN: 1538-4047,1555-8576
DOI: 10.4161/cbt.8.14.8889